MissionIR today announces that its interview with Dan O’Conner, the president and Chief Executive Officer of Advaxis, is now available online. The audio interview can be heard at http://adxs.missionir.com/interview.html.
In the interview, O’Conner provides crucial details of Advaxis’ technology and lead drug candidate ADXS-HPV, and provides highlights of completed, current and upcoming clinical trials for several indications, including cervical cancer.
Advaxis is operated by a highly experienced management team with numerous years of pharmaceutical development, business and other relative experience. O’Conner describes the backgrounds and qualifications of several key members of Advaxis management, as well as details his own 50 years of executive involvement in the biopharmaceutical industry.
In his comprehensive review of the company, O’Conner also touches on Advaxis’ business outlook for 2013 and its overall business strategy and financial viability.
“We intend to seek an uplisting for national exchange in the near term,” says O’Conner. “We strongly believe that the combination of completing the reverse split of our stock and the contemplated uplisting could heighten the interest of the financial community in Advaxis as well as potentially broaden the pool of investors as they consider investing in the company while strengthening financial health.”
For additional information, please visit: www.ADXS.MissionIR.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment